Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)
Brief Summary
MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. Ecstasy use has also been associated with rare cardio- and cerebrovascular complications. The role of beta-blockers in the treatment of cardiovascular and adverse effects of MDMA is unknown.
Condition or Disease
- Mood Disorder
- Substance-Related Disorders
- Amphetamine-Related Disorders
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Completed |
| Study results: | No Results Available |
| Age: | 18 Years to 45 Years (Adult) |
| Enrollment: | 16 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Jun 01, 2001 | |
|---|---|---|
| Primary Completion: | Mar 01, 2002 | |
| Completion Date: | Mar 01, 2002 | |
| Study First Posted: | May 08, 2009 | |
| Results First Posted: | Aug 30, 2020 | |
| Last Updated: | Jun 15, 2009 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
We investigated the interactive effects of the beta-blocker pindolol (20 mg) with MDMA (1.6 mg/kg) on heart rate, blood pressure, body temperature, and adverse effects in a double-blind placebo-controlled study in 16 healthy subjects.
Eligibility Criteria
| Sex: | Male |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 45 |
More Details
| NCT Number: | NCT00895804 |
|---|---|
| Other IDs: | E-003/2001 |
| Study URL: | https://ClinicalTrials.gov/show/NCT00895804 |
Last updated: Jun 17, 2022